Although many cannabis experts and industry insiders were hoping to see a change in cannabis’ federal classification before the upcoming Presidential election in November, the Drug Enforcement Administration (DEA) has scheduled a hearing for December 2 to consider expert opinions on the Department of Justice’s proposal to reschedule marijuana from a Schedule I to a Schedule III drug under the Controlled Substances Act (CSA). This follows a public comment period that received over 40,000 submissions, leading to the decision to hold an administrative hearing after the November elections.
The hearing introduces some uncertainty into the timeline for the potential rescheduling, raising concerns that the rulemaking process may not be completed before January, potentially complicating the transition under a new administration. Despite hopes from some advocates for a quicker resolution, the DEA regularly schedules hearings for major public interest regulatory proposals, and this case is no exception.
If the rescheduling is finalized, cannabis would be subject to the same regulatory controls as other Schedule III substances, while still maintaining specific restrictions under federal law. While some advocates have argued that this development would set the stage for state-legal cannabis markets to be taken over by large pharmaceutical companies, many industry stakeholders believe that Schedule III will enable access to much-needed financial services and remove the burden of IRS Tax Code 280E, which prevents cannabis businesses from deducting any normal business expenses on their tax returns.
The itinerary for the DEA’s upcoming hearing has not yet been laid out, though in all likelihood it will feature presenters from both sides of the debate. Interested parties who may be affected by the policy change must submit a notice of intent to participate in the hearing within 30 days of the notice’s publication.
Get daily cannabis business news updates. Subscribe
Ganjapreneur is made possible by our partners:
